2012 Midyear Clinical Meeting
Click here to go to the previous page
Management Case Studies L: Part 1
Track:
Education Sessions (CE)
Program Code: 374-L05
Date: Wednesday, December 5, 2012
Time: 8:00 AM to 8:30 AM EST
Location:
South Seas B, Level 3, South Convention Center
PRESENTER(S):
Dr. Leigh DeMarco, PharmD, MS, Pharmacy Manager, Huntsman Cancer Hospital
Carolyn Kowalchik,
RPh, MSs, Director of Pharmacy,
University of Utah Hospitals & Clinics
Carolyn Kowalchik is the Pharmacy Service Director at the University of Utah Hospital. Her areas of interest include medication safety, accreditation, residency programming and use of technology in providing excellent pharmacy services. She is a graduate of the University of Utah (BS and MS).
|
Dr. Brad Myers, PharmD, MBA, BCPS, System Director, Sentara Healthcare
Linda Tyler,
PharmD, Administrative Director, Pharmacy Services,
University of Utah Hospitals & Clinics
Dr. Linda Tyler is the Administrative Director of Pharmacy Services, University of Utah Hospitals & Clinics, and Associate Dean, College of Pharmacy. She is responsible for the comprehensive pharmacy services of 4 hospitals, 4 infusion services, 14 retail pharmacies, ambulatory clinical services and the Drug Information Service (DIS). She serves as residency program director for the 2 year Health System Pharmacy Administration/ MS program. Previously, Dr. Tyler was Director of the DIS at Utah. During her tenure, the DIS developed national prominence. The DIS provides the content information for the ASHP Drug Shortages Resource Center and contract services for many national organizations. Dr. Tyler has served ASHP as a Board Member for Clinical Specialists and on the Council for Pharmacy Practice Management. She led the expert panel to revise the guidelines on formulary management and pharmacy & therapeutic committees. She is recognized as a Fellow in ASHP. She has participated in the AHRQ Patient Safety Corp Training program. Her areas of interest include leadership development, new drugs, literature evaluation, medication safety, drug shortages, evidence based decision making, and drug policy development.
|
PROGRAM CHAIR:
Brian Esuchanko
Description
Using Failure Mode Effects Analysis (FMEA) to Improve Controlled Substances Processes in Inpatient Areas
- Describe the steps of a FMEA.
- Identify three factors to make a FMEA project more successful.
- List three system vulnerabilities for handling controlled substances that can be identified through a FMEA process.